Yoshida J, Wakabayashi T, Kato K, Enomoto H, Kito A, Kageyama N
Gan To Kagaku Ryoho. 1986 Mar;13(3 Pt 1):520-4.
In order to analyze the efficacy of combination therapy with Hu-IFN-beta, ACNU and radiation (IAR), nine patients with malignant glioma were treated as a control study. They received 100 X 10(4) IU Hu-IFN-beta daily for seven days intravenously or intratumorally, 3 mg/kg ACNU on day 2 and 5,000-6,000 rads of radiation from day 3. Four out of nine patients showed complete response and one partial response with this IAR therapy. Case 1 was a 64-year-old man who had glioblastoma in the left frontal lobe. Postoperative residual tumors disappeared completely with this therapy. Case 3 was a 8-year-old girl who had an enhanced high-density lesion in the medulla oblongata and pons. After IAR therapy, the high-density lesion was completely vanished and her clinical manifestations of multiple cranial nerve palsy and pyramidal sign were improved remarkably. The major side effects of IAR therapy were mild or moderate myelosuppression, and some patients also showed hepatic dysfunction, mild fever and gastrointestinal toxicities. However, all these side effects were mild and transient and soon recovered to normal levels. These results suggest that IAR therapy is effective and will prolong the survival time of patients with malignant glioma.
为分析人β干扰素（Hu-IFN-β）、嘧啶亚硝脲（ACNU）与放疗联合治疗（IAR）的疗效，对9例恶性胶质瘤患者进行了对照研究。他们在第1至7天每天静脉或瘤内注射100×10⁴IU Hu-IFN-β，第2天和第5天给予3mg/kg ACNU，从第3天开始给予5000 - 6000拉德的放疗。9例患者中有4例显示完全缓解，1例部分缓解。病例1是一名64岁男性，左额叶患有胶质母细胞瘤。经该治疗后，术后残留肿瘤完全消失。病例3是一名8岁女孩，延髓和脑桥有强化的高密度病变。IAR治疗后，高密度病变完全消失，其多组颅神经麻痹和锥体束征的临床表现明显改善。IAR治疗的主要副作用为轻度或中度骨髓抑制，部分患者还出现肝功能障碍、低热和胃肠道毒性。然而，所有这些副作用均较轻且为一过性，很快恢复至正常水平。这些结果表明，IAR治疗有效，且将延长恶性胶质瘤患者的生存时间。
